Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT)
fell 51.4% in the afternoon session after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) rejecting the company's New Drug Application for relacorilant.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT)
fell 4.7% in the afternoon session after investor anxiety mounted ahead of a key U.S. Food and Drug Administration (FDA) decision for its drug candidate, relacorilant.
Corcept has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13.8% to $81.75 per share while the index has gained 13.9%.
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT)
fell 9.2% in the afternoon session after investment bank UBS initiated coverage of the company with a Neutral rating.
Corcept Therapeutics (CORT) combines strong fundamentals, including robust revenue growth and a healthy balance sheet, with a positive technical breakout setup.
Discover Corcept Therapeutics (CORT), a debt-free pharma stock with strong growth forecasts, solid profitability, and a reasonable valuation for balanced investing.
Growth boosts valuation multiples, but it doesn’t always last forever.
Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.
Looking back on branded pharmaceuticals stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Corcept (NASDAQ:CORT) and its peers.
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied.
This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia pulled back after SoftBank sold its stake. This "hurt the AI trade," dragging down related names like Micron and Oracle.
As capital left tech, it sought safety in "higher quality" defensive names. Health care giants like Merck, Amgen, and Johnson & Johnson saw significant buying, boosting the Dow.
Corcept Therapeutics’ third quarter results drew a negative market reaction as the company’s revenue missed Wall Street expectations, despite robust year-on-year growth. Management highlighted persistent capacity constraints with its former specialty pharmacy partner as a key factor limiting revenue capture. President of Endocrinology Sean Maduck explained, “Our financial results don’t fully reflect the surge in demand,” attributing recent bottlenecks to insufficient pharmacy capacity. The company has since begun transitioning to a new pharmacy, aiming to better meet rising prescription volumes and position Corcept for future growth.
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results that are validating extensive research and development efforts across the industry. Investors are demonstrating a renewed appetite for risk,
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 13.7% year on year to $207.6 million. The company’s full-year revenue guidance of $825 million at the midpoint came in 3.3% below analysts’ estimates. Its GAAP profit of $0.16 per share was 21.8% above analysts’ consensus estimates.
Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the markets revenue expectations in Q3 CY2025, but sales rose 13.7% year on year to $207.6 million. The company’s full-year revenue guidance of $825 million at the midpoint came in 3.3% below analysts’ estimates. Its GAAP profit of $0.16 per share was 18.4% above analysts’ consensus estimates.
